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Abstract
We have previously shown that TPA activates HTLV-1 LTR in Jurkat T-cells by inducing the binding of Sp1-p53 complex to
the Sp1 site residing within the Ets responsive region 1 (ERR-1) of the LTR and that this activation is inhibited by PKCalpha
and PKCepsilon. However, in H9 T-cells TPA has been noted to activate the LTR in two consecutive stages. The first stage is
activation is mediated by PKCetta and requires the three 21 bp TRE repeats. The second activation mode resembles that of
Jurkat cells, except that it is inhibited by PKCdelta. The present study revealed that the first LTR activation in H9 cells
resulted from PKCetta-induced elevation of non-phosphorylated c-Jun which bound to the AP-1 site residing within each
TRE. In contrast, this TRE-dependent activation did not occur in Jurkat cells, since there was no elevation of non-
phosphorylated c-Jun in these cells. However, we found that PKCalpha and PKCepsilon, in Jurkat cells, and PKCetta and
PKCdelta, in H9 cells, increased the level of phosphorylated c-Jun that interacted with the Sp1-p53 complex. This interaction
prevented the Sp1-p53 binding to ERR-1 and blocked, thereby, the ERR-1-mediated LTR activation. Therefore, this PKC-
inhibited LTR activation started in both cell types after depletion of the relevant PKCs by their downregulation. In view of
these variable activating mechanisms we assume that there might be additional undiscovered yet modes of HTLV-1 LTR
activation which vary in different cell types. Moreover, in line with this presumption we speculate that in HTLV-1 carriers the
LTR of the latent provirus may also be reactivated by different mechanisms that vary between its different host T-
lymphocyte subclones. Since this reactivation may initiate the ATL process, understanding of these mechanisms is essential
for establishing strategies to block the possibility of reactivating the latent virus as preventive means for ATL development
in carriers.
Citation: Abou-Kandil A, Chamias R, Huleihel M, Godbey WT, Aboud M (2012) Differential Role of PKC-Induced c-Jun in HTLV-1 LTR Activation by 12-O-
Tetradecanoylphorbol-13-acetate in Different Human T-cell Lines. PLoS ONE 7(1): e29934. doi:10.1371/journal.pone.0029934
Editor: Kylene Kehn-Hall, George Mason University, United States of America
Received July 25, 2011; Accepted December 7, 2011; Published January 27, 2012
Copyright:  2012 Abou-Kandil et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by grants from the Israel Science Foundation and from the Israel Cancer Research Fund. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: aboud@bgu.ac.il
Introduction
Adult T-cell leukemia (ATL) is etiologically associated with
human T-cell leukemia virus type 1 (HTLV-1) infection [1,2].
Accumulating data indicate that the HTLV-1 bZipper protein
(HBZ), originally discovered by Gaudray et al [3], plays an
important role in the ATL pathology [4–7]. Other studies have
attributed a similar importance for the ATL pathology to the
HTLV-1- induced modulation of cellular microRNAs (miRNA)
expression [8–11]. However, the multifunctional viral Tax
oncoprotein is widely regarded as the critical factor for initiating
the leukemic process leading to this malignancy. This role of Tax
is linked mainly to its abilities to activate constitutive expression of
major regulatory factors like the NF-kB [12–17] and to impair the
cellular genome stability, which are reflected by enhanced DNA-
mutagenesis and chromosomal aberrations, including chromo-
somal aneuploidy, on one hand [14,18–22] and protecting the
cells from the DNA damage-induced apoptosis on the other hand
[14,20–25]. In addition, a recent study has demonstrated that Tax
induces reactive oxygen species (ROS) in a way that correlates
with DNA damage and expression of cellular senescence markers,
but not with apoptosis [26]. Since similar correlation of ROS
induction with genomic instability, cellular senescence and
tumorigenesis has been reported for several oncogenes like Myc
[27,28], Ras [29] and the EBV nuclear antigen-1 [30], it has been
suggested that this pathway might be involved also in the HTLV-
1leukemogensis.
Notably, shortly after infection the virus enters into a latent state
[14,18,19,31] during which Tax level in the carriers’ infected T-
lymphocytes is very low due to suppression of the viral gene
expression [14,31]. However, despite this low virus expression,
substantial levels of specific antibodies and cytotoxic T-lympho-
cytes (CTLs) against Tax and other HTLV-1 antigenic epitopes
can be detected in these carriers [14,32–35]. Accumulating data
indicate that these two arms of the anti HTLV-1 immune response
play critical roles in suppressing the viral gene expression and
conferring, thereby, its latency [14,32–34,36–39].
The low Tax level is presumably insufficient for exerting its
complex oncogenic effects [14,31]. Therefore, only a small
minority (5–10%) of these carriers eventually develop ATL after
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the transition from latency to the leukemic progression occurs in
these particular carriers due to reactivation of the latent virus,
which consequently elevates Tax level to its oncogenic threshold.
Moreover, since the initial Tax level in the virus-harboring cells is
very low, it is reasonable to assume that this reactivation initiates
by a Tax-independent mechanism. Furthermore, since the ATL
cells contain no or very low Tax level [14,19,40] we assume that
this reactivation is likely temporal. We speculate that the
activated virus returns, after a while, back to latency due to re-
mounting of the host anti HTLV-1 immune surveillance
mentioned above. This presumption implies that the transiently
elevated Tax may initiate the leukemic process, in a hit-and-hide
manner. We postulate that during the temporal time of the virus
activation, Tax may initiate the leukemic process by enhancing
mutagenesis and other chromosomal aberrations in its harboring
cells while protecting them from apoptosis induction
[14,20,41,42]. In this manner, some of these cells may acquire
certain specific mutations that render them permanently resistant
to apoptosis. Such cells can then further progress toward ATL by
a stepwise accumulation of additional mutations even after re-
silencing the activated virus and shutting off its Tax protein. This
model complies with the low ATL incidence and the long time
required for its development.
ATL is an aggressive lethal malignancy [1,2] that does not
respond to presently available anti cancer medications [7,43].
Therefore, in addition to the current intense effort focused in
many laboratories on developing new effective curing therapies for
ATL [43–45], we suppose that it would be highly important to
concentrate effort also on establishing strategies for blocking the
possibility for developing this malignancy in healthy carriers. Of
interest, in this context, is the study of Afonso et al [46] which has
demonstrated in series of baboons naturally infected with simian
T-lymphotropic virus type 1 (STLV-1), that treatment with a
combination of valproate (an inhibitor of histone deacetylases) and
azidothymidine (an inhibitor of reverse transcriptase) efficiently
decreases their proviral load. Based on this model, the authors
suggest that such treatments may be useful to reduce the risk of
HAM/TSP in healthy HTLV-1 carriers with high proviral load.
However, in view of the putative model of ATL development
described above, it seems that avoiding potential re-activation of
the dormant virus might be an ideal approach for achieving this
aim in HTLV-1 carriers. A support to this idea has emerged from
a recent study of Ratner et al [40] which indicates that the
inefficiency of the chemotherapy treatment of ATL results from
re-activation of the dormant virus harbored in the leukemic cells
by the DNA damage- and stress-inducing effects of the
chemotherapeutic drugs. Taken together, blocking the potential
re-activation of the dormant virus might both, prevent ATL
development in healthy HTLV-1 carriers and improve the
outcomes of the chemotherapy treatment in ATL patients.
Establishing such an approach requires a deep understanding of
the various optional complex mechanisms and factors that might
potentially induce this viral reactivation.
In pursuing this issue, we have previously noted that HTLV-1
LTR expression can be activated in various human T-cell lines
and primary T-lymphocytes by DNA-damaging and other
stressing-inducing agents in absence of Tax [41,47]. These
findings suggest that environmental or intrinsic stress-inducing
factors might trigger the viral re-activation in latent carriers by
similarly activating its LTR. It should be pointed, however, that all
the LTR-activating agents that we have tested can also induce
apoptosis [41]. Moreover we have proved that this LTR activation
depends on certain factor(s) participating in the apoptotic cascade
by showing that it can be abrogated by the anti apoptosis factor
Bcl-2 [41]. It might have seemed paradoxical to expect that
reactivation of the virus by a mechanism that sets the host cells of
the activated virus into apoptotic death, can lead to ATL.
However, this apparent paradox has been reconciled by our
observation that HTLV-1 infected T-cells, which display active
viral gene expression, are protected by the viral Tax protein from
apoptosis induction by such stress agents [41]. This finding implies
that the Tax protein, emerging after re-activation of the dormant
virus, can rescue its host cells from apoptosis and enable their
leukemogenic progression.
In the last few years we have focused mainly on the activation of
HTLV-1 LTR by 12-O-tetradecanoylphorbol-13-acetate (TPA)
[41,47–49]. This phorbol ester is a potent PKC activator [50]
which can induce DNA damage by generating reactive oxygen
species (ROS) [51–53]. Therefore, it can serve as an experimental
model for revealing possible mechanisms of re-activation of the
dormant virus in HTLV-1 carriers by certain PKC-activating
physiological and pathological processes involving ROS produc-
tion [54–57]. Our recent study [47] has shown that, although TPA
activates the same PKC isoforms (a, b1, b2, d, e, and g) in both
Jurkat and H9 human T-cell lines, these cells vary from each other
in the rate of the ubiquitin-mediated downregulation of these
PKCs [58] and in the effect of each individual PKC on the LTR
expression. Moreover, these differences in the PKC characteristics
have been proved to confer two different cell-type-dependent
modes of LTR activation by TPA in these two cell lines. In Jurkat
cells this activation is exerted via binding of an Sp1-p53 complex
to Sp1 site residing within the 44 bp Ets responsive region-1
(ERR-1) located between the nucleotides 2160 and 2116 away
from the transcription starting point of the LTR [47,49]. This
binding is inhibited by PKCa and PKCe. Therefore, the onset of
the LTR activation occurs in these cells only after 12–24 hr of
TPA treatment, i.e. the time that these two PKCs are depleted
from these cells.
By contrast, in H9 cells TPA has been noted to activate the
LTR in two consecutive phases. The first phase starts shortly after
exposing the cells to TPA and peaks after 36–48 hr of TPA
treatment. This activation depends on PKCg activity which is
depleted from these cells only after 48–60 hr of TPA treatment
and it critically requires the involvement of all the three repeated
21 bp Tax responsive elements (TRE) of the LTR [47]. The
second phase starts after 72 hr of TPA treatment. Its mechanism is
analogous to that of Jurkat cells, except that it is inhibited by
PKCd, which is also depleted from H9 cells only after 48–60 hr of
TPA treatment [47]. Interestingly, the potent PKC inhibitor,
bisindolylmaleimide-I (BI) [59], inhibits all the above mentioned
PKC isoforms in both cell types, except PKCd, which is sensitive
to this inhibitor in Jurkat but resistant to it in H9 cells [47].
Therefore, BI can abolish the PKCa and PKCe antagonism to the
LTR activation in Jurkat cells but not the PKCd antagonism in H9
cells [47].
The aim of the present study was to identify the downstream
factors mediating the specific effects of these PKC isoforms on the
LTR expression in these two T-cell lines. Our experiments
revealed that the first LTR activation phase in H9 was mediated
by non-phosphorylated c-Jun that was transiently elevated in these
cells by PKCg and that this elevated form of c-Jun activated the
LTR by its binding to the AP-1 site residing in each of its three
21 bp TRE repeats. No such TRE-dependent LTR activation was
observed in Jurkat cells, since only phosphorylated c-Jun, which
could not bind to the AP-1 site, was elevated in these cells by
PKCa and PKCe. Phosphorylated c-Jun was transiently elevated
in H9 cells too, but this elevation was mediated by PKCd. In both
Role of c-Jun in TPA-Induced HTLV-1 LTR Activation
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p53 complex and inhibited, thereby, its binding to ERR-1.
Consequently the onset of the ERR-1-dependent LTR activation
occurred in both cell lines only after depletion of their phospho-c-
Jun-elevating PKCs by their downregulation.
Results
Transient elevation of phosphorylated and non-
phosphorylated c-Jun in TPA-treated H9 cells
We began this study by exploring the mechanism of the first
phase of the LTR activation in the TPA-treated H9 cells. We have
previously noted that this activation requires all the three 21 bp
TRE repeats and that a single nucleotide substitution at the AP-1
binding sequence (see in ‘‘Materials and Methods’’) of any of these
TREs abolished this activation [47]. Furthermore, Jeang et al have
shown that c-Jun activates the HTLV-1 LTR by binding to these
AP-1 sites [62]. In addition, TPA-activated PKC isoforms have
been reported to induce the expression of c-Jun and to affect its
functions [65–67]. Collectively, these data prompted us to
investigate whether TPA induced the first LTR activation phase
by affecting c-Jun expression. Western blot analysis of c-Jun level
in the whole cell extracts of TPA-treated H9 cells with anti c-Jun
antibody revealed a transient increase of a massive band that
peaked at 36–48 hr of the TPA treatment (Figure 1A row 1).
However, in addition to this band, this antibody detected also an
upper thinner band. To clarify the nature of these two bands the
blotted filter was reprocessed with anti phospho-c-Jun antibody
that specifically identifies c-Jun protein phosphorylated at serine
residues 63 and 73. Figure 1A row 2, shows that this antibody
identified only one band that was identical to the upper band
noted in row 1 in terms of its electrophoretic migration and
intensity. These results indicated that the upper band represented
a c-Jun protein phosphorylated at serine residues 63 and 73,
whereas the lower band, seen in row 1, evidently presented a c-Jun
without this phosphorylation (that we referred to as c-Jun or non-
phosphorylated c-Jun).
Role of PKCg and PKCd in the c-Jun/phospho c-Jun
elevation
The decline of these two bands (Figure 1A, rows 1 and 2)
coincided with the timing of the PKCg and PKCd depletion from
the TPA-treated H9 cells noted in our previous study [47]. In
addition, we have previously found that PKCg suppresses the
activity of PKCd [47]. Therefore, it seemed reasonable to assume
that PKCg alone was involved in the elevation of both c-Jun
forms. However, this presumption was refuted by our next finding
that the PKC inhibitor BI abolished only the lower band of the
non-phosphorylated c-Jun, but not the upper band of the
phospho-c-Jun that was detected by both, the anti c-Jun
(Figure 1A row 4) and the anti phospho-c-Jun (Figure 1A row 5)
antibodies. Of note in this context, we have previously shown also
that in H9 cells BI inhibited the activity of PKCg but not of PKCd
[47]. On this ground the results presented in Figure 1 can be
explained by postulating that in absence of BI the active PKCg
suppressed the activity of PKCd and therefore, only PKCg could
evidently be involved in the elevation of both forms of c-Jun
(Figure 1A, rows 1 and 2). On the other hand, blocking PKCg
activity by BI most likely relieved the PKCg-mediated suppression
of the BI-resistant PKCd. Therefore, the single band remaining in
these conditions, which was detected by both, the anti c-Jun
(Figure 1A rows 4) and the anti phospho-c-Jun (Figure 1A rows 5)
antibodies, was evidently of phospho-c-Jun that was elevated by
the reactivated PKCd. This presumption was supported by the
following set of observations: (a) Knockdown of PKCd with
specific shRNA in absence of BI had no effect on the elevation of
either of these two c-Jun forms (Figure 1B, rows 1 and 2). This
finding confirmed that the active PKCg alone could indeed,
elevate both of the c-Jun forms. (b) Knockdown of PKCd in the
presence of BI diminished the elevation of both c-Jun forms
(Figure 1B rows 4 and 5). This finding confirmed that the BI-
reactivated PKCd was responsible for the phospho-c-Jun elevation
in absence of PKCg which is shown in Figure 1A rows 4 and 5. (c)
Knockdown of PKCg by shRNA led to elevation of only the
phospho-c-Jun in both absence (Figure 1C rows 1 and 2) and
Figure 1. Transient Elevation of c-Jun and phospho-c-Jun by PKCg and PKCd in TPA-treated H9 cells. H9 cells (A) and their subclones
stably transfected with shRNAs against either PKCd (B) or PKCg (C), were treated with TPA in absence (rows 1 to 3) or presence (rows 4 to 6) of the
PKC inhibitor BI. Aliquots of the whole-cell extracts, prepared at the indicated times of the TPA 6 BI treatment, were subjected to Western blot
analysis with monoclonal antibody against c-Jun (rows 1 and 4). Then the blots were re-processed with anti phospho-c-Jun antibody (rows 2 and 5).
Equal sample loading was assessed by re-processing the blotted filter with anti actin antibody (rows 3 and 6). (D) Elevation of c-Jun and
phospho-c-Jun by ectopically introduced PKCg and PKCd. H9 cells were transfected with plasmids expressing constitutively active PKCg or
PKCd in the absence or presence of BI. At 24 hr post transfection the cells were examined for the level of c-Jun and phospho-c-Jun by Western blot
analysis as detailed for panels A, B and C. Non-transfected cells served as control.
doi:10.1371/journal.pone.0029934.g001
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confirmed that the absence of PKCg activity permitted PKCd to
elevate phospho-c-Jun even in the presence of BI. (d) Transfecting
TPA-non-treated H9 cells with plasmid expressing constitutively
active PKCg resulted in elevation of the two c-Jun forms which
were both abolished BI, whereas transfecting these cells with
plasmid expressing constitutively active PKCd elevated only the
phospho-c-Jun and this elevation was unaffected by BI (Figure 1D).
Interestingly, the elevation time-course of the two c-Jun forms in
the TPA-treated H9 cells (Figure 1A rows 1 and 2) closely
correlated to the timing of first LTR activation phase that we
previously noted in these cells [47]. However, while our previous
study revealed that BI abolished the first LTR activation phase
[47], the present experiment demonstrated that this inhibitor
prevented only the elevation of the non-phosphorylated but not of
the phosphorylated c-Jun (Figure 1 rows 4 and 5). These data
suggest that the non-phosphorylated c-Jun, but not the phospho-c-
Jun might be participating in this first LTR activation phase.
Only the non-phosphorylated c-Jun binds to the 21 bp
TRE repeats
Next, we explored why the non-phosphorylated rather than the
phosphorylated-c-Jun was involved in this LTR activation and
whether it exerted this effect directly or through an additional
mediator. As mentioned before, Jeang et al [62] have reported that
Jun activates the LTR by binding to its TRE sites. Based on this
report, we elucidated whether the differential LTR activating
potential of these two c-Jun forms, observed in our present
experiment, reflected a variation in their TRE-binding capacity.
This was done by examining the binding of the nuclear proteins of
H9 cells at various time-points of their TPA treatment to the 39-
biotin-labeled TRE-III oligonucleotides probe shown in ‘‘Materi-
als and Methods’’ and Figure 2A, which was arbitrarily chosen as
a representative TRE. The EMSA results depicted in Figure 2B
revealed two bands which were marked as I and II. The intensity
of band I transiently increased, peaking at 36–48 hr of the TPA
treatment and then declined and was undetected at 72 hr of the
treatment. On the other hand, band II was not affected by this
treatment.
The specificity of these bands was assessed by a competition
with 50 fold molar excess of unlabelled w.t. 21 bp TRE-III
oligonucleotide and its mutant illustrated in ‘‘Materials and
Methods’’ and Figure 2A. This analysis was carried out with the
nuclear extract of cells treated with TPA for 36 hr, which, as noted
in our previous study [47], was the peak time-point of the first
LTR activation phase. Figure 2C shows that the unlabeled w.t.
TRE-III oligonucleotide completely abolished both bands whereas
no competition was displayed by the mutant oligonucleotide.
The proteins forming these bands were identified by supper-
shift analyses with the indicated antibodies. To ensure the
reliability of this assay increasing doses of the tested antibodies
were employed. Figure 2D revealed that low dose (1 mg) of
antibody against the non-phosphorylated c-Jun supershifted only
part of the TPA-responding band I to position Ia, whereas higher
doses of this antibody quantitatively supershifted increasing
amounts of this band, reaching a saturation at about 2 mg of the
antibody. However, no supershift of this band was detected with
the anti phospho-c-Jun antibody. These data indicated that only
the non-phosphorylated c-Jun was involved in forming this band.
On the other hand, band II was supershifted by anti CREB
Figure 2. Binding of c-Jun and CREB of the TPA-treated H9 cells to TRE III. (A) Schematic illustration of the U3 region of the LTR. In addition,
this scheme illustrates the employed probes carrying the wild type (w.t.) and the mutated TRE III sequences. (B) Aliquots of nuclear extracts prepared
from H9 cells at the indicated times of the TPA treatment were analyzed by electrophoretic mobility shift assay (EMSA) for binding to 39 biotin labeled
oligonucleotide probe carrying the w.t. TRE III sequence. (C) The specificity of this binding was assessed with nuclear proteins of the cells prepared
after treatment with TPA for 36 hr. This was done by competition with 50 fold molar excess of unlabeled oligonucleotides carrying the w.t (left lane)
versus the mutant TRE III (right lane) sequences. (D) The nuclear proteins of the 36 hr TPA-treated H9 cells that bound to the TRE III probe were
identified by supershift analysis with the indicated doses of antibodies against CREB, ATF-1, ATF-2, c-Jun and phospho-c-Jun. (E) BI effect on the
nuclear protein binding to TRE III was determined by testing it the nuclear extracts of the H9 cells treated for 36 hr with TPA6BI. (F) H9 cells (control)
and their sub-clones carrying either the anti CREB or anti c-Jun shRNA were treated with TPA for 36 hr. Then their nuclear extracts were subjected to
EMSA with the labeled TRE III probe. (G) Illustration of the knockdown efficiency of CREB (upper blot) and phospho/none-phospho c-Jun by their
specific shRNA (lower blot) in H9 cells treated with TPA for 36 hr.
doi:10.1371/journal.pone.0029934.g002
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manner. This band was not affected by anti c-Jun and anti
phospho-c-Jun antibodies and conversely anti CREB antibody had
no effect on band I (Figure 2D). These findings are in lne with the
presumption that c-Jun and CREB cannot concomitantly bind to
the same molecules of this probe, since their binding sites in the
TREs share partially overlapping sequences [62]. Furthermore,
consistent with this conclusion, Figure 2E shows that BI abolished
the formation of band I by the PKCg-induced non-phosphory-
lated c-Jun, but not of the PKC-independent formation of band II
by CREB. In addition, this BI-mediated inhibition of band I
formation indicated that phospho-c-Jun, which was elevated in H9
cells by the BI resistant PKCd (see Figure 1C), could not bind to
TRE. This finding re-confirmed that only the non-phosphorylated
c-Jun was involved in band I formation.
The activating transcription factor (ATF) family includes a large
group of leucine zipper (bZIP) transcription factors [68] that
regulate the expression of many cellular and viral genes in
response to a wide range of intrinsic or external signals [69–71].
Under certain circumstances members of this family form
transcriptional regulatory complexes with CREB (CREB/ATF)
that bind to CRE sites of various promoters [72]. CREB/ATF-1
and CREB/ATF-2 have been reported to bind to the CRE site
located in each of the 3 TREs of the HTLV-1 LTR [63,64,73].
These reports prompted us to check whether ATF-1 and/or ATF-
2 joined CREB in forming band II in our present experiments.
However, this possibility was ruled out by the results illustrated in
Figure 2 D which demonstrated that band II was not supershifted
by anti ATF-1 or anti ATF-2 antibody. To further substantiate the
notion that band I was formed only by the non-phosphorylated c-
Jun and band II by CREB, we used H9 cells stably transfected
with anti CREB or anti c-Jun shRNA. These cells were treated
with TPA for 36 hr (the peak time-point of the first the LTR
activation phase) and examined for CREB and c-Jun binding to
the 39 biotin labeled TRE III probe. Cells without shRNA served
as control. Figure 2F shows that, while the extract of the control
cells formed both bands I and II. On the other hand, the extract of
the cells carrying the anti CREB shRNA did not form band II,
whereas the extract of the cells carrying the anti c-Jun shRNA did
not form band I.
Next, we analyzed the binding of nuclear proteins of the TPA 6
BI treated H9 cells to the TRE III probe by the DNA-protein pull-
down assay described in ‘‘Materials and Methods’’. Figure 3A
demonstrates that in absence of BI the amount of the non-
phosphorylated c-Jun pulled-down by the anti c-Jun antibody,
transiently increased, peaking at 36 hr of the TPA treatment and
then depleted from the cells at 54–72 hr of the treatment. On the
other, hand no pull-down of phospho-c-Jun was detected by the
Figure 3. DNA-protein pull-down and Chromatin immunoprecipitation (ChIP) analyses of binding of nuclear proteins of TPA±BI
treated H9 cells to TRE III. (A) For the DNA-protein pull-down analysis, nuclear extracts were prepared from H9 cells after treatment with TPA6BI
for the indicated times. Aliquots (200 mg protein) of these extracts were reacted with 6 mgo f3 9-biotin-labeled TRE III probe and further processed as
detailed in ‘‘Materials and Methods’’, using the indicated antibodies for identifying the specifically bound proteins. (B) The same analysis was
performed as in panel A except that limiting dose (1 mg) of the 39-biotin-labeled probe was employed in order to check for binding competition
between c-Jun and CREB on the limited available AP1 site. (C) The same extracts were subjected to Western blot analysis for assessing the input of all
the proteins tested in the experiment of panels A and B. To visualize an intracellular recruitment of nuclear proteins of H9 cells to TREs of a putative
integrated HTLV-1 viral genome during the first and the second phases of the TPA-induced LTR activations we employed the ChIP procedure
described in ‘‘Materials and Methods’’. This was done with chromatins derived from H9 cells carrying stably transfected LTR-Luc plasmid (H9/LTR-Luc),
that were exposed to TPA for 36 hr (the peak time-point of the first phase) or for 96 hr (the second phase). (D) These cells were assessed, first, for the
activation of the integrated LTR-Luc in both time-points of the TPA treatment (right and middle panels). Untreated cells served as control (left
column). The depicted results represent the average of the triplicate assays 6 SE. Then the chromatin of the cells treated with TPA for 36 hr (panel E)
and 96 hr (panel F) was subjected to ChiP analysis for binding of CREB, c-Jun, ATF-1, ATF-2 and phospho-c-Jun using the indicated doses of the
corresponding precipitating antibodies.
doi:10.1371/journal.pone.0029934.g003
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BI avoided the binding of the non-phosphorylated c-Jun to this
probe. These data substantiate our earlier notions that band I is
formed only by the non-phosphrylated c-Jun (see Figure 2D) and
that BI avoids the formation of this band (see Figure 2E) by
blocking the PKCg-induced elevation of the non-phosphrylated c-
Jun (see Figure 1A row 5 and 1B row 4). The binding specificity of
the nuclear proteins of these cells to TRE III was confirmed by our
next finding that non-phosphorylated c-Jun was not pulled down
in a similar assay using the mutated 39-biotin labeled TRE III
oligonucleotide (data not shown).
As noted above, CREB and c-Jun cannot bind jointly to the
same individual TRE III probe molecule due to their partial
overlapping binding site. This notion can readily be illustrated by
EMSA since this assay reveals two separate bands (see Figure 2B
and 2D) whose proteins can be identified by supershift with
specific antibodies (see Figure 2D) and by distinguishing which of
them is abolished by BI (see Figure 2E). However, it is rather more
complicated to illustrate this exclusive binding to different
individual molecules of the probe by the DNA-protein pull-down
procedure. To overcome this obstacle we employed a small
amount (1 mg) of the labeled probe, which was adjusted to be
limiting factor that forced CREB and c-Jun to compete for its
binding. The results depicted in Figure 3B show, indeed, that
when c-Jun level was elevated by TPA it displayed an increasing
binding to the probe that was paralleled by a reciprocal decline of
the CREB binding, whereas this CREB binding to the probe was
gradually restored along with the downregulation of the c-Jun level
at longer TPA treatment.
As expected, CREB binding to this probe was not affected by
TPA nor by BI (Figure 3A). This finding supported our conclusion
from the data presented in Figure 2D that CREB was not involved
in the LTR activation by TPA. Moreover, neither ATF-1 nor
ATF-2, were found to bind to this probe although, as can be seen
in Figure 3C, they were detected by the Western analysis of the
input proteins tested in Figures 3A and 3B. This finding thus re-
confirmed that ATF-1 and ATF-2 did not participate in the first
phase of the TPA-induced LTR activation.
In the next experiment, we employed the ChIP assay for
visualizing an in vivo recruitment of the nuclear factors to the
TREs of integrated HTLV-1 DNA in the cellular genome. This
was done with the H9 cells stably transfected with LTR-Luc (H9/
LTR-Luc) which provided a convenient cellular system for this
assay. These cells were treated with TPA for 36 hr (i.e. the peak
time point of the c-Jun/phospho-c-Jun elevation) and 96 hr (i.e.
when c-Jun and phospho-c-Jun were already depleted from the
cells, see Figure 1A). We analyzed first the TPA activation of the
integrated LTR-Luc. Figure 3D demonstrates that this reporter
was substantially stimulated at both time-points of the TPA
treatment. Then the fragmented chromatin of these cells was
immunoprecipitated by increasing amounts of the indicated
antibodies and the DNA was purified from the precipitated
fragments and amplified by real-time PCR with primers flanking
the region spanning the three TREs of the LTR. Figure 3E shows
that at 36 hr of the TPA treatment these TRE-containing DNA
fragments were precipitated by both the anti CREB and the anti c-
Jun antibodies and that in both cases the amount of the
precipitated fragments increased along with the increasing doses
of the antibodies, reaching a saturation at 2 mg antibody. Notably
at this time point of the TPA treatment the amount of the
fragments precipitated with anti c-Jun antibody was considerably
higher than that which was precipitated with the anti CREB
antibody, thus confirming that the level of c-Jun was higher than
that of CREB. On the other hand, Figure 3F shows that at 96 hr
of the TPA treatment, i.e. when no c-Jun was left in the cells (see
Figure 1A), chromatin precipitation was detected only with anti
CREB antibody. Moreover, the amount of the fragments
precipitated by this antibody was higher at the 96 hr than at the
36 hr time-point. This finding indicates that there was no c-Jun at
the 96 hr time-point to compete with CREB for the TRE. In
addition, no precipitation of these fragments was detected with
antibodies against ATF-1, ATF-2 and phospho-c-Jun in both time-
points, which further confirmed that these factors were not
involved in the LTR activation by TPA.
Direct confirmation that only the non-phosphorylated c-
Jun mediates the first phase of the LTR activation in TPA-
treated H9 cells
It was important, at this stage, to assess the biological roles of
the two c-Jun forms in the cellular mechanism of the first LTR
activation phase in the TPA-treated H9 cells. For this purpose we
explored, first, the effect of c-Jun knockdown on this activation by
exposing H9 cells stably transfected with the plasmid expressing
anti c-Jun shRNA (H9/c-Jun-shRNA) and their parental H9 cells
to TPA for 36 hr, which was the peak time-point of the first LTR
activation phase. As control for the specificity of this shRNA, we
employed, in parallel, H9 cells stably transfected with an
arbitrarily chosen irrelevant shRNA-expressing plasmid, like the
anti p53 shRNA (H9/p53 shRNA). Part of these cells were used
for measuring the level of c-Jun in their whole cell extracts by
Western blot analysis, whereas the remaining cells were transfect-
ed with the LTR-Luc reporter and tested for its expression at
24 hr post-transfection. This experiment revealed that the anti c-
Jun shRNA almost completely abolished the elevation of both c-
Jun forms (Figure 4A, upper panel) and strongly reduced the LTR
activation (Figure 4B), whereas the anti p53 shRNA, which
strongly inhibited p53 formation (not shown), was ineffective in
both parts of this experiment (Figures 4A and 4B). To find out
which of the two c-Jun forms mediated this LTR activation, TPA-
untreated H9 cells were transfected with LTR-Luc alone (control)
or together with c-Jun-expressing plasmid that produced only non-
phosphorylated c-Jun (see Figure 4C), or with plasmid expressing
ectopic PKCd which, as noted before, elevated only phospho-c-
Jun (see Figure 1C). This experiment revealed that the ectopic
non-phosphorylated c-Jun markedly stimulated the LTR-Luc
expression in H9 cells, whereas the PKCd-elevated phospho-c-
Jun was slightly inhibitory (Figure 4D, left panel). As expected,
neither the ectopic c-Jun nor the ectopic PKCd had any effect on
the LTR-Luc expression in H9/c-Jun-shRNA (Figure 4D, right
panel).
TPA induces in Jurkat cells a transient elevation of only
phospho-c-Jun through a cooperative action of PKCa
and PKCe
To explore why Jurkat cells do not display the TRE-mediated
LTR activation by TPA [47] we investigated the effect of TPA on
their c-Jun status. Western blot analysis of the whole-cell extracts
of these cells revealed that anti c-Jun antibody detected a transient
elevation of only one band (Figure 5 B, row 1) which was
recognized also by the anti phospho-c-Jun antibody (Figure 5 B,
row 2). This finding indicates that in Jurkat cells TPA induces an
elevation of only the phospho-c-Jun. This elevation peaked at 6–
12 hr of the TPA treatment. Its subsequent decline (Figure 5A,
rows 1 and 2) coincided with the previously reported timing of
PKCa and PKCe depletion from these cells [47]. Moreover, our
present experiment demonstrated that this elevation was blocked
by BI (Figure 5A, rows 4 and 5). Since both PKCa and PKCe
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observations can be interpreted as suggesting that the phospho-c-
Jun elevation was mediated either by one of these PKCs or by a
cooperative action of both of them. To distinguish between these
possibilities we examined the elevation of phospho-c-Jun in TPA-
treated Jurkat cells stably transfected with anti PKCa shRNA
(Jurkat/PKCa-shRNA) or anti PKCe shRNA (Jurkat/PKCe-
shRNA). Figure 5B shows that both PKCa and PKCe were
strongly suppressed by their specific shRNAs. Nevertheless,
although the phospho-c-Jun elevation was substantially reduced
by this strong silencing of PKCa (Figure 5C) or PKCe Figure 5D),
this inhibition was incomplete (compare the bands in these figures
to those of Figure 5A rows 1 and 2). Only when both shRNAs
were introduced (Jurkat/PKCa+PKCe), the elevation of phospho-
c-Jun was almost completely omitted (Figure 5 E). These data
indicated that both PKCs jointly participated in achieving the full
extent of this elevation. Knockdown of PKCg (Figure 5F) and
PKCd (Figure 5G) by their specific shRNAs had no effect on the
phospho-c-Jun elevation, thus confirming the specificity of the
Figure 4. The first LTR activation phase in TPA-treated H9 cells
is mediated by the non-phosphorylated c-Jun. H9 cells and their
subclones stably transfected with c-Jun shRNA (H9/c-Jun shRNA) or
with p53 shRNA (H9/p53 shRNA) were treated with TPA for 36 hr (the
peak time-point of the first phase). (A) Whole cell extracts were
prepared from part of the treated cells for measuring the level of the
non-phosphorylated c-Jun (c-Jun) by Western blot analysis with anti c-
Jun antibody. Equal sample loading was assessed by re-processing the
blotted filter with anti actin antibody. TPA-untreated H9 cells without
shRNA served as negative control, whereas TPA-treated H9 cells without
shRNAs served as positive control. (B) The remaining cells were
transfected with the LTR-Luc reporter. TPA-untreated cells without
shRNAs served as negative control and TPA-treated cells without
shRNAs served as positive control. The pRL-renilla plasmid was included
in this and all the subsequent transient transfection experiments as
internal control for assessing variation in the transfection efficiency. The
enzymatic activities were measured at 24 hr post transfection and the
Luc activity was normalized to that of renilla and plotted as fold of the
respective control. The documented results presented the average of
triplicate transfections 6 SE. (C) H9 cells without (left panels) and with
(right panels) anti c-Jun shRNA were transfected with plasmid
expressing non-phosphorylated c-Jun (ectopic c-Jun) or with plasmid
expressing constitutively active PKCd which elevates only phospho-c-
Jun. Cells without these ectopic plasmids served as control. At 24 hr
after transfection the whole cell extracts of the transfected and non-
transfect cells were subjected to Western blot analysis with anti-c-Jun
antibodies (top panels) and with antibodies detecting only phosphor-
ylated c-Jun (middle panels). Equal sample loading was assessed with
anti actin antibody (bottom panels). (D) H9 cells (left panel) and their
subclone stably transfected with anti c-Jun shRNA (H9/c-Jun shRNA,
right panel) were transiently transfected with LTR-Luc alone (control) or
together with ectopic c-Jun- or ectopic PKCd- expressing plasmids.
Calculation of the enzymatic activities and their presentation were as in
Figure 4B.
doi:10.1371/journal.pone.0029934.g004
Figure 5. Role of PKCa and PKCe in the phospho-c-Jun
elevation in TPA-treated Jurkat cells. (A) Jurkat cells were treated
with TPA in absence (rows 1–3) or presence (rows 4–6) of the inhibitor
BI. Aliquots of the whole-cell extracts, prepared from the cells at the
indicated times of the TPA6 BI treatments, were subjected to Western
blot analysis, first with anti c-Jun, then with anti phos-c-Jun and finally
with anti actin antibody as in Figure 1. Panel (B) shows the efficiency of
the specific shRNA-mediated knockdown of the indicated PKCs isoforms
to be employed in the experiments illustrated in the next panels. Jurkat
subclones stably transfected with anti PKCa (B) or anti PKCe (C) shRNAs
or with both of them (D) were treated with TPA6 BI for the indicated
times and then examined by Western blot for the level of phos-c-Jun
and actin panel (A). As negative control, similar analyses were
performed with Jurkat cells transfected with anti PKCg (F) or anti PKCd
(G) shRNAs. To quantify the effect of these knockdowns on the level of
the tested c-Jun and phosho-c-Jun we performed densitometry
measurements of the bands in the original exposed films of the
Western blots. The results are presented as % of the largest band in
Figure 1A row 1 which was designated as 100%. To assess the
knockdown effects of the employed shRNAs on their target PKC
isoforms (G), whole cell extracts of Jurkat cells without (left) or with
(right) the specific shRNA against the indicated PKCs were subjected to
Western blot analysis with the respective antibodies.
doi:10.1371/journal.pone.0029934.g005
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the TPA-treated Jurkat cells.
Jurkat cells display only CREB binding to TRE but can be
rendered to display TRE-dependent LTR activation by
ectopic c-Jun
Next, we examined the TRE oligonucleotide binding by nuclear
proteins of TPA-treated Jurkat cells. This was done by exposing
the cells to TPA for 12 hr, which was their peak timing of the
phospho-c-Jun elevation (see Figure 5A). Figure 6A shows that the
nuclear proteins of these cells formed only one band which was not
affected by TPA or BI. Since all the TPA-activated PKC isoforms
of Jurkat cells have been previously shown to be sensitive to the
inhibitory effect of BI [47], the present data indicated that none of
the TPA activated PKCs of Jurkat cells was involved in the
formation of this band. Furthermore, the present experiment
suggested that this band was analogous to band II of H9 cells in
terms of its electrophoretic migration (compare Figure 6A and 6B
to Figure 2) and supershift pattern by the increasing amounts of
anti CREB antibody (compare Figure 6B to Figure 2C). It
resembled band II of H9 cells also in being unaffected by excessive
amounts of the anti phospho-c-Jun, anti ATF-1 and anti ATF-2
antibodies (compare Figure 6B to Figure 2C) nor by TPA or BI
(compare Figure 6A with Figure 2D). Moreover, since TPA
elevated in these cells only phospho-c-Jun (see Figure 5A), the lack
of band I formation by their extracts (Figures 6A and 6B) provided
additional evidence that only non-phosphorylated c-Jun could
bind to TREs. This conclusion was further substantiated by the
following experiment in which TPA-non-treated Jurkat cells were
transfected with a c-Jun-expressing plasmid. Similarly to our
finding with H9 cells (Figure 4C), the Western blot analysis
depicted in Figure 6C illustrates that this construct produced only
non-phosphorylated c-Jun in Jurkat cells too. Consequently, the
nuclear extract of these c-Jun-transfected Jurkat cells could now
form two EMSA bands with the TRE III probe instead off one.
Moreover, the new band was identical to band I of H9 cells in its
slower electrophoretic migration and its specific supershift by anti
c-Jun antibody but not by the anti-phospho-c-Jun antibody
(Figure 6D). In addition, Figure 6E shows that this ectopic c-Jun
markedly stimulated the LTR-Luc expression in Jurkat cells.
Collectively, these data demonstrated that the non-phosphorylated
c-Jun, which was encoded by the ectopic c-Jun plasmid, enabled
Jurkat cells to form band I by its interaction with the TREs and to
display, thereby, the TRE-dependent LTR activation. This
evidence excluded the possibility that some other factors, beside
the lack of non-phosphorylated c-Jun elevation, might prevent the
TRE-dependent LTR activation in these cells in response to TPA
treatment.
Sp1-p53 complex mediates the second LTR activation
phase in TPA-treated H9 cells
In a previous study we have shown that the PKC-antagonized
LTR activation in Jurkat cells is mediated by binding of an Sp1-
p53 complex to the Sp1 site located within the ERR-1 of the LTR
[49]. Subsequently we have noted that the second phase of the
LTR activation in TPA-treated H9 cells is exerted through the
same site in ERR-1 [47]. Therefore, it was of interest to find out
whether this second LTR activation phase was mediated by a
similar interaction of Sp1-p53 complex with ERR-1. We
addressed this question by analyzing the binding of nuclear
proteins of the TPA6BI-treated H9 cells to the 39-biotin-labeled
w.t. ERR-1 probe described in ‘‘Materials and Methods’’. The
EMSA results depicted in Figure 7 B illustrate that during the first
48 hr of the TPA treatment only one band was noted at position
II, whereas at later stages of this treatment (i.e. during the second
phase of the LTR activation), an additional slower and much
thicker band was detected at position I. The specificity of these
binding was confirmed by competition analysis of the extract
derived from cells treated with TPA for 96 hr, which was
arbitrarily chosen to represent the second LTR activation phase.
Figure 7 C shows that both bands were competed out by a 50 fold
excess of unlabeled w.t. ERR-1 oligonucleotide, while the same
excess of the mutated ERR-1 oligonucleotide which carried 3
nucleotide substitutions within its Sp1 site (see the schematic
illustration in Figure 7A), eliminated the lower band (band II) but
not the upper one (band I). As shown in Figure 7A, ERR-1
includes also binding sites for several additional factors. It is
therefore, possible that one or more of these sight might, perhaps,
Figure 6. Binding of Jurkat’s nuclear proteins to TRE probe. (A)
Jurkat cells were treated with TPA 6 BI for 12 hr and then their nuclear
extracts were analyzed by EMSA for binding to the 39-biotin-labeled TRE
probe. (B) The protein that forms band II was determined by supershift
analysis with the indicated amounts of the specified antibodies. (C)
Jurkat cells were transfected with ectopic c-Jun expressing plasmid,
whereas non-transfected cells served as control. Their whole cell
extracts were analyzed at 24 hr after transfection by Western blot with
the indicated antibodies for the level of non-phosphorylatedc-Jun
(designated as c-Jun-top panel) and phosphorylated c-Jun (designated
as phos-c-Jun middle panel). Equal protein loading was assessed by
processing the blot of with anti actin antibody (bottom panel). (D)
Jurkat cells were transfected with ectopic c-Jun and at 24 hr after
transfection their nuclear extracts were subjected to supershift analysis
with the indicated doses of the specified antibody. (E) Jurkat cell were
co-transfected with LTR-Luc and ectopic c-Jun expressing plasmid. Cells
without ectopic c-Jun served as control. Calculation of the enzymatic
activities and their presentation were as in Figure 4B.
doi:10.1371/journal.pone.0029934.g006
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structure [74–77]. However, since this band was unaffected by
TPA, it seemed to be irrelevant to the TPA-induced LTR
activation and therefore, we did not try to identify its protein
composition. Furthermore, the unlabeled TRE III oligonucleotide
(shown in Figure 2A), which we employed as an irrelevant
competitor, had no effect on either of these bands, thus further
substantiating the binding specificity of these bands. Interestingly,
these two bands appeared to be analogous to bands I and II that
we have previously noted in the TPA-treated Jurkat cells [49].
Moreover, in both cell types band I was detected only after a
substantial delay of 12–24 hr in Jurkat [49] and 48–72 hr in H9
(Figure 7A) cells. Of note, however, BI diminished this delay in
Jurkat [49], but not in H9 cells (Figure 7B). This finding is
consistent with our previous notion that the delay in the onset of
the second LTR activation phase in H9 cells is caused by the BI-
resistant PKCd [47].
Figure 7D illustrates a supershift analyses of the nuclear extract
derived from the H9 cells treated with TPA for 96 hr, i.e. during
the second LTR activation phase. This analysis revealed that
increasing amounts of anti Sp1 antibody supershifted band I to
position Ia in a dose-dependent manner, whereas similar doses of
the DO-1 antibody, which recognized both w.t. and mutant p53
proteins, displayed a stronger supershift that moved band I to
position Ib. These different supershifts could be interpreted as
indicating that band I represented two separate DNA-protein
Figure 7. Binding of the Sp1-p53 complex to the Sp1 site of the ERR-1 in TPA ± BI treated H9 cells. (A) Schematic illustration of the ERR-1
probe sequene: The upper probe carries the wild type sequence whereas the lower probe is mutated by 3 substituted nucleotides within the Sp1
binding site depicted in small underlined letters. (B) H9 cells were treated with TPA 6 BI for the indicated times and aliquots of their nuclear extracts
were tested for binding to 39 biotin-labeled w.t. ERR-1 probe by EMSA. (C) The specificity of this protein binding to the ERR-1 probe was determined
in nuclear extract of cells treated with TPA for 96 hr (i.e. at the second phase of the LTR activation). This was done by competition with 50 molar
excess of unlabeled oligonucleotide carrying the w.t. or the mutated ERR-1 sequence. For additional control we employed the same excess of the
oligonucleotide carrying the TRE III sequence (shown in ‘‘Materials and Methods’’ and Figure 2A) as an irrelevant competitor. (D) The proteins bound
to the ERR-1 probe, were identified by supershift analysis of the nuclear extract derived from H9 cells treated with TPA for 96 hr using 1, 2 and 4 mg
ofthe following antibodies: anti albumin (as an irrelevant negative control), or with anti Sp1 and the DO-1 anti p53 (which detect both the w,t. and
mutant p53 proteins). A combination of anti Sp1 and anti p53 antibodies (1 and 2 mg of each of them) was employed in the last 2 lanes at the right
side of the blot, whereas no antibody was employed in the control cells presented in the first lane at the left side of the blot. (E) To determine
whether the Sp1-p53 complex that bound to the ERR-1 probe contained w.t. or mutant p53 protein, a similar supershift analysis was performed with
pAb1620 antibody which identified only w.t. p53 and pAb240 antibody that identified only mutant p53. (F) To demonstrate the intracellular
recruitment of these nuclear proteins to the ERR-1 site in LTR integrated within the cellular genome, we carried out chromatin immunoprecipitation
(ChIP) analysis in the H9 cells stably transfected with LTR-Luc (H9/LTR-Luc) which were treated with TPA for 96 hr. The immunoprecipitation was
performed with 2, 4 and 8 mg of each of the indicated antibodies. (G) Jurkat/LTR-Luc cells were tested for activation of their integrated LTR-Luc by
48 hr-TPA-treatment. Untreated Jurkat/LTR-Luc cells served as control. (H) Jurkat (left panel) and H9 (right panel) cells were co-transfected with the
pG13-Luc reporter and BRCA1-expressing plasmid in the absence and presence of anti p53-shRNA. Cells without BRCA1 expressing plasmid served as
basal control.
doi:10.1371/journal.pone.0029934.g007
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happened to display a similar electrophoretic mobility but they
were differently supershifted by their respective antibodies which
formed, perhaps, complexes with different structural configura-
tion. However, this possibility was ruled out by our finding that
when the anti Sp1 and the DO-1 antibodies were applied together
band I was not splitted to the distinct positions Ia and Ib, but was
rather supershifted further as a single band to position Ic. No
supershift was imposed by the irrelevant anti albumin antibody
(Figure 7D), thus verifying the specificity of this assay. These
supershift data closely resembled our previous observation with
nuclear extract derived from Jurkat cells after 48 hr of TPA
treatment [49]. Of note, however, Figure 7E shows that pAb240
antibody, which recognizes only mutant p53, displayed the same
supershift of band I as the DO-1 antibody, whereas the pAb1620
antibody, which recognizes only w.t. p53, did not impose any
supershift on band I. These data are contrasting our previous
finding with Jurkat cells which have demonstrated that both
pAb240 and pAb1620 antibodies formed two new different
supershifted bands while leaving a portion of the original band I
unshifted [49]. Therefore, we re-assessed our present observation
by subjecting H9 and Jurkat cells to chromatin immunoprecipi-
tation (ChIP) assay that was performed with their subclones stably
transfected with the LTR-Luc construct (H9/LTR-Luc). The
integrated LTR-Luc was effectively stimulated by TPA in both H9
(see Figures 3D) and Jurkat (see Figures 7F) cells. The upper row of
Figure 7G shows that anti Sp1 and the DO-1 anti p53 antibodies
pulled down comparable amounts of the real-time PCR-amplified
DNA fragments obtained from the chromatin of H9/LTR-Luc
cells treated with TPA for 96 hr. Since these fragments do not
contain specific sites for direct p53 binding [74–77], the ability of
the DO-1 anti p53 antibody to pull them down indicates that p53
was recruited to ERR-1 through its physical protein-protein
association with the Sp1 protein. This row of Figure 7G shows also
that the pAb240 antibody, which recognizes only mutant p53,
could precipitate ERR-1 fragments, whereas the pAb1620
antibody, which recognizes only w.t. p53, could not. By contrast,
the lower row of Figure 7G demonstrates that all the three anti
p53 antibodies pulled down comparable amounts of the
fragmented chromatin from the TPA-treated Jurkat cells as the
anti Sp1 antibody. This discrepancy can be explained by our
previously reported evidence that Jurkat cells contain both w.t.
and mutant forms of p53 [49], whereas H9 cells contain only
mutant p53 [23]. To further substantiate this notion we examined
these two cell lines for endogenous w.t. p53 specific transcriptional
activity by using a reporter driven by a minimal promoter attached
to 13 copies of the w.t. p53 specific responsive site (pG13) as target
for this activity. The breast cancer sensitivity BRCA1 protein has
been reported to act as transcriptional coactivator of the w.t. p53
protein by physically interacting with this protein and enhancing,
thereby, its transcriptional function [78,79]. Based on this
information Jurkat and H9 cells were examined for BRCA1-
inducibale endogenous w.t. p53 transcriptional activity by co-
transfecting the cells with the pG13-Luc reporter and BRCA1-
expressing plasmid. The left panel of Figure 7H shows that this co-
transfection strongly activated the pG13-Luc reporter in Jurkat
cells. Moreover, this activation was suppressed by anti p53 specific
shRNA, thus confirming that it was mediated by an endogenous
w.t. p53 existing in these cells. In contrast, no such pG13-Luc
activation was detected in H9 cells (Figure 7H, right panel). The
Western blots inserted in both panels of Figure 7H illustrate that
the BRCA1 and the anti p53 shRNA plasmids displayed equally
high expression in both cells. This finding, together with our
earlier reported data [23,49], confirmed that unlike our Jurkat
cells, the H9 cells employed in the present study, contain only
mutant p53. This mutant is evidently deficient of the w.t. p53
specific transcriptional activity but is still able to interact with
certain other factors and to affect their functions.
Phospho-c-Jun associates with the Sp1-p53 complex and
blocks its binding to ERR-1
The time-course of the phospho-c-Jun elevation in the TPA-
treated H9 (Figure 1) and Jurkat (Figure 3) cells correlates the
delayed binding of the Sp1-p53 to ERR-1 in both H9 (see
Figure 7B ) and Jurkat (see ref. [49]) cells. This correlation pointed
to the possibility that this delay was imposed by physical
interaction of the elevated phospho-c-Jun with the Sp1-p53
complex. We search for such physical interaction by reciprocal
co-immunoprecipitation analyses of the nuclear extracts of these
cells at the indicated time-points of their TPA treatment. We
found that the immunoprecipitates pulled down by the DO-1 anti
p53 antibody from the nuclear extracts of the Jurkat (Figure 8A,
left panels, rows 1 and 2) and H9 (Figure 8B, left panels, rows 1
and 2) included the Sp1 protein during their entire exposure to
TPA. Conversely, the precipitates that were pulled down by anti
Sp1 antibody included p53 protein (Figure 8A, left panels, rows 4
and 5 for Jurkat cells and Figure 8B, left panels, rows 4 and 5 for
H9 cells). On the other hand, the precipitates that were pulled
down by anti p53 or anti Sp1 antibody included phospho-c-Jun (c-
Jun-P) only during its elevation time. i.e. 6–12 hr of the TPA
treatment in Jurkat cells (Figure 8A, left panels, rows 3 and 6) and
24–48 hr of the TPA treatment in H9 cells (Figure 8B, left panels,
rows 3 and 6). Furthermore, the precipitates that were pulled
down by the anti c-Jun-P contained all the three protein
components in both cells, but only during the phospho-c-Jun
elevation time (see Figure 8A left panels for Jurkat cells and
Figure 8B left panels for H9 cells). The results depicted in the right
panels show that BI did not affect the association between p53 and
Sp1 (Figure 8A, right panels, rows 1, 2, 4 and 5 for Jurkat cells and
Figure 8B, right panels, rows 1, 2, 4 and 5 for H9 cells). BI
abolished, however, the association of c-Jun-P to the Sp1-p53
complex in Jurkat (Figure 8A, right panels, rows 3, 6, 7, 8 and 9),
most likely by inhibiting the PKCa and PKCe-mediated phospho-
c-Jun elevation in these cells (see Figure 5A, rows 4 and 5). In
contrast, BI did not interfere with this association in H9 cells
(Figure 8B, right panels, rows 3, 6, 7, 8 and 9), since it could not
avoid the phospho-c-Jun elevation by the BI-resistant PKCd (see
Figure 1C, rows 4 and 5). Figures 8A and 8B show also that no
association between Sp1 and p53 occurred in the TPA-un-treated
Jurkat and H9 cells. In summary, these data together indicated
that TPA triggered the association between Sp1 and p53 in both
cell lines through a mechanism that was neither dependent on, nor
interfered by any of the TPA-activated BI-sensitive PKCs. The
possible involvement of theBI-resistant PKCd in this association
within H9 cells was also excluded by our previous observation that
silencing PKCd by specific shRNA did not abort the second phase
of the LTR activation in these cells [47].
Notably the binding of phospho-c-Jun to Sp1-p53 coincided
with the delay in the Sp1-p53 binding to ERR-1for more than
48 hr of the TPA treatment in H9 (see the above Figure 7B) and
for more than 12 hr in Jurkat cells (see ref. [49]). To explore
whether the phospho-c-Jun binding to Sp1-p53 caused these
delays, we re-assessed the binding of this complex to ERR-1 in the
two cells types stably transfected anti c-Jun shRNA. Figures 8C
(Jurkat/anti c-Jun shRNA) and 8D (H9/anti c-Jun shRNA) show
that knockdown of c-Jun totally alleviated this delay in both cells
by permitting this binding immediately after the beginning of the
TPA treatment.
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Jun accounted for the delay in the onset of the PKC-antagonized
LTR activation by TPA, we examined the effect of c-Jun
knockdown with specific shRNA on this delay. Figure 8E shows
that c-Jun silencing diminished this delay in Jurkat cells. For
examining the effect of c-Jun silencing in H9 cells, the TPA
treatment had to be carried out in the presence of BI in order to
avoid the first phase of the LTR activation, since otherwise this
first phase would mask any effect on the early steps of the second
phase. Figure 8F shows that under such conditions the second
phase started, indeed, with no delay.
Schematic summary of the PKC/c-Jun LTR activation
pathways in the TPA-treated H9 and Jurkat Cells
Figure 9 schematically summarizes the different roles of the
various TPA-activated PKC isoforms in the HTLV-1 LTR
activation in H9 (panel A) and Jurkat (panel B) cells and the
functions of the PKC-elevated phosphorylated and non-phosphor-
ylated c-Jun in the different downstream mechanisms of the LTR
activation.
Discussion
Our earlier search for environmental factors that might be
involved in reactivation of the dormant virus in HTLV-1
asymptomatic carriers has revealed that HTLV-l LTR can be
activated in various human T-cell lines and primary T-
lymphocytes by DNA-damaging and other stress-inducing agents
in absence of Tax [41]. Of these agents we have focused mainly on
the LTR activation by TPA [41,47–49] for the reasons discussed
in the ‘‘Introduction’’ section.
We have recently noted that although TPA activates in Jurkat
and H9 cells the same set of PKC isoforms (a, b1, b2, d, e, g), their
functional activities and the rate of their TPA-mediated down-
regulation varied between these two cell types. For instance,
PKCg and PKCg persist in the TPA-treated H9 cells much
longer (more than 48 hr) than in Jurkat cells (about 12 hr only).
Moreover, we have noted that in H9 cells PKCg activity
suppresses the activities of the other isoforms, whereas in Jurkat
cells PKCg activity is suppressed by PKCa and PKCe [47]. Along
with these differences, we have discovered two distinct mecha-
nisms of TPA-induced LTR activation in these cells. One of them
Figure 8. Reciprocal co-immunoprecipitation analysis of phospho c-Jun binding to the Sp1-p53 complex and evidence for its
involvement in the delay of the PKC-antagonized LTR activation. Jurkat (A) and H9 (B) cells were treated with TPA for the indicated times in
absence (left panels) or presence (right panels) of BI. Aliquots of their nuclear extracts were immunoprecipitated with mouse antibodies (Mouse IP
Ab) against p53 (DO-1) (rows 1, 2, 3), Sp1 (rows 4, 5, 6) and phospho-c-Jun (rows 7, 8, 9) as detailed in ‘‘Materials and Methods’’. The co-
immunoprecipitated proteins were dissociated and identified by Western blot analysis with the respective rabbit antibodies (Western Rabbit Ab). To
determine whether the phospho-c-Jun binding to the Sp1-p53 complex accounted for the delay of the binding of this complex to ERR-1, c-Jun was
knockdown by shRNA in Jurkat (panel C; Jurkat/c-Jun shRNA) and H9 (panel D; H9/c-Jun shRNA) cells. These cells were treated with TPA for the
indicated times and their nuclear extracts were examined by EMSA for binding to the 39-biotin-labeled ERR-1 probe as described in ‘‘Materials and
Methods). To explore whether the phospho-c-Jun binding to the Sp1-p53 complex accounted for the delay in the onset of the PKC-antagonized LTR
activation by TPA, the Jurkat/c-Jun shRNA cells (panel E) were treated with TPA whereas H9/c-Jun shRNA were pretreated with TPA+BI. Cells without
the anti c-Jun served as control. At the indicated times of these treatments the cells were transfected with LTR-Luc. The enzymatic activity was
measured at 24 hr post-transfection and plotted as describe in Figure 4B.
doi:10.1371/journal.pone.0029934.g008
Role of c-Jun in TPA-Induced HTLV-1 LTR Activation
PLoS ONE | www.plosone.org 11 January 2012 | Volume 7 | Issue 1 | e29934is strictly dependent on PKCg and transiently operates only in H9
until this isoform is depleted from the cells. This mechanism does
not operate in Jurkat cells since, as noted above, PKCg activity is
suppressed in these cells by PKCa and PKCe [47]. The other
mechanism operates in both cells. It is rather antagonized by
specific PKC isoforms and, therefore, its onset is delayed until
these particular PKCs are depleted from the cell due to their
downregulation by the extended exposure to TPA. In H9 cells this
mechanism is antagonized by PKCd [47], whereas in Jurkat cells it
is antagonized by a joint action of PKCa and PKCe [41,47].
In the present study we observed that PKCg induced the first
LTR activation phase in H9 cells by transiently increasing the level
of c-Jun. A small portion of the elevated c-Jun was phosphorylated
at serine residues 63 and 73, whereas its the vast majority was non-
phosphorylated. The non-phosphorylated c-Jun proved to induce
this LTR activation by its direct binding to the three 21 bp TRE
repeats. No such PKC-dependent LTR activation was observed in
Jurkat cells, since PKCa and PKCe suppressed the activity of
PKCg in these cells [47], while elevating only phospho-c-Jun,
which proved to be incapable of binding to the TRE repeats.
In exploring the mechanism of the PKC-antagonized mode of
the LTR activation, we have found in our previous studies that in
Jurkat cells TPA activates the LTR by inducing the formation of
an Sp1-p53 complex which binds to an Sp1 site residing within the
ERR-1 domain of the LTR [41,49]. These studies have also
shown that the Sp1-p53 binding to ERR-1 is interfered in these
cells by PKCa and PKCe and that this interference can be
alleviated by BI [41,49]. In the present study we found that the
phospho-c-Jun, which was cooperatively elevated in these cells by
PKCa and PKCe physically interacted with the Sp1-p53 complex
and blocked its binding to ERR-1. Consequently, the onset of the
LTR activation was delayed for 12–18 hr, i.e. until these two
PKCs were depleted from the cells by their downregulation.
Notably, the PKC-antagonized LTR activation in H9 cells was
delayed for much longer time (48–60 hr) but, in contrast to Jurkat
cells, it was unaffected by BI in these H9 cells [47]. In addition, we
found here that the BI-abolished inhibition of the Sp1-p53 binding
to ERR-1 in Jurkat cells was exerted by blocking the PKCa/
PKCe-mediated phospho-c-Jun elevation. The failure of this
inhibitor to do so in H9 cells proved to result from the phospho-c-
Jun that was elevated in these cells by their BI-resistant PKCd,
which was released from its BI-inhibited PKCg-mediated
suppression. TPA and other PKC activators are known for a long
time as activators of c-Jun expression and functions [65]. The N-
Figure 9. Schematic summary of the TPA-induced LTR activation pathways in (A) H9 and (B) Jurkat cells.
doi:10.1371/journal.pone.0029934.g009
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c-Jun N-terminal kinases JNK1, JNK2 and JNK3 (JNKs). It
contains also phosphorylation sites and transactivation domain
[80]. Under certain conditions the c-Jun N-terminal phosphory-
lation by JNKs at seine residues 63 and 73 and theronine residues
91 and 93, stimulates the c-Jun transcriptional activity, whereas in
some other conditions the phosphorylation of serine 63 and 73
increases c-Jun capacity to physically interact with other binding
partners [80,81]. Notably the phospho-c-Jun detected in our
experiments, was proven to be phosphorylated at serine 63 and 73,
by showing that it was recognized by an antibody that specifically
identifies these phosphorylated residues (see Materials and
Methods). It is, therefore, reasonable to assume that this specific
phosphorylation accounted for its physical association with the
Sp1-p53 complex observed in our experiments. Moreover, several
recent reports, which have shown that TPA can induce JNK-
mediated c-Jun phosphorylation in certain cells [82–85]. On this
ground, we speculate that the TPA-activated PKC isoforms, which
elevated the phospho-c-Jun level in our present study, exert this
effect indirectly through specific JNK activation.
Interestingly, while the binding of the Sp1-p53 to ERR-1 has
been noted in our previous studies to be interfered by PKC [41],
no effect of PKC was detected in the present study on the
formation of this complex in H9 cells, which occurred in these cells
shortly after TPA addition to the cells. Based on these findings we
hypothesize that TPA triggers the apoptotic cascade by inducing
PKC-independent DNA-damaging oxidative burst [86] and that
certain, undefined yet, factors of the early stage of the apoptotic
cascade might induce this rapid Sp1-p53 complex formation.
EMSA analysis of the Sp1-p53 binding to ERR-1 revealed that
the DO1 antibody, which recognized both w.t. and mutant p53
proteins, displayed a stronger supershift of the Sp1-p53 related
band than the anti Sp1 antibody. This could argue that band I
consisted of two complexes, that happened to display similar
electrophoretic mobility, but could be separately supershifted by
their specific antibodies. This argument was declined by our
observation with extracts of Jurkat cells that employing the anti
Sp1 and anti p53 antibodies together shifted the original band I as
a single band to a higher position III. If band I consisted, indeed,
of two separate complexes, then the shift with the two antibodies
together should have splitted it into two separate bands. In
addition, we have found in our previous study [49] that the
pAb1620 antibody, which recognizes only w.t. p53, and the
pAb240 antibody, which recognizes only mutant p53, formed two
new different supershifted bands while leaving a portion of the
original band unshifted [49]. Together with this latter finding, it
appears that p53 exists in this complex at a two fold higher molar
quantity than Sp1, which in the case of Jurkat cells, it includes
both the w.t. and the mutant p53 forms. Therefore, higher amount
of the DO1 anti p53 than the anti Sp1 antibody can bind to the
band I complex. Furthermore, in another study with Jurkat cells
we have observed that the Sp1-p53 complex binds also to an Sp1
recognition site residing in the p21Waf-1 promoter and presents
similar EMSA and supershift patterns [87]. Thus, while several
laboratories claim that their Jurkat cells are p53-null [88,89], our
findings in these studies indicate that our Jurkat cells contain
comparable levels of both w.t. and mutant p53 proteins.
Moreover, in the present study we demonstrated that Jurkat cells
contained p53 protein that displayed w.t. p53 specific transcrip-
tional activity. Similar p53 status was observed also by Gualberto
et al in their Jurkat cells [90,91]. In contrast, analyses, performed
in the present study with H9 cells, revealed that these cells contain
only mutant p53. This notion is compatible with earlier reported
immunostaining [92] and immunoprecipitation [49,92] analyses
which could detect in H9 cells only mutant p53. However, it
remains unclear from these data whether only complexes with
mutant p53 molecules, which are formed in both Jurkat and H9
cells, are effective in activating the LTR or whether those with w.t.
p53 formed in Jurkat cells are effective as well.
Finally, it is important to note that p53 is one of the most
commonly mutated genes in human cancers [93,94]. Many
different mutations have been identified in p53 of tumor cells.
Most of these mutations abrogate its specific affinity towards the
w.t. p53 DNA responsive element, while others confer upon it new
oncogenic properties [95] or affect its protein conformation [96].
However, very little is known about the linkage between particular
p53 mutations to specific clinical outcomes [93,94].
Conclusions
Our results raise the question as to which of the two
mechanisms discussed above operates in the infected T-cells of
HTLV-1 carriers. We like to emphasize that in addressing this
question it should be kept in mind that the individual infected T-
cells of the HTLV-1 carriers are likely heterogenic and vary in
several aspects. Of particular relevance to the viral reactivation
issue is the variation in the level of the viral gene expression
between different individual infected T-cells, which ranges from
high to very low expression. The level of the viral gene expression
in each individual infected cell is likely determined by the
integration site of the proviral DNA in the host cell genome.
Integration within condensed DNA regions permits lower viral
gene expression than in relaxed DNA regions. Cells with high viral
gene expression are believed to be eliminated by the host immune
surveillance [14,97]. Therefore, it should not be surprising if PKC-
activating physiological or pathological conditions may reactivate
the latent virus in different infected individual cells by different
mechanisms. Furthermore, we are currently investigating the
mechanisms of LTR activation by other PKC-unrelated stress-
inducing agents that might differ from those associated with PKC.
Since blocking the latent virus reactivation is highly important for
preventing the leukemic process in HTLV-1 carries, it is essential
to explore all possible reactivation mechanisms in order to develop
specific drugs against each of them. These drugs should be
prescribed as cocktails that HTLV-1 carriers will have to take for
their entire life as is currently done, for example, with HIV carriers
and certain other clinical conditions.
Materials and Methods
Plasmids and transfection
The reporter plasmid expressing the firefly luciferase through
HTLV-1 LTR (LTR-Luc) was provided by Susan J. Marriott
(Baylor College of Medicine, Houston, TX). The plasmid
expressing w.t. Tax through the CMV promoter, was provided
by Francoise Bex (Laboratore de Microbiologie, Universite Libre
de Bruxelles, B-1070, Brussels, Belgium). The plasmid pG13-Luc,
expressing luciferase through a minimal promoter containing 13
copies of the w.t. p53-consensus binding sequence, was obtained
from Moshe Oren (Weizman Institute of Science, Rehovot, Israel).
The BRCA1-expressing plasmid [60] was from Haim Werner
(Department of Clinical Biochemistry, Sacler School of Medicine,
Tel Aviv University, Tel Aviv, 69978, Israel). The pZL plasmids
expressing constitutively active PKC isoform a, b1, b2, c, d, e and
g [61] were provided by Etta Livne (Faculty of Health Sciences,
Ben-Gurion University of the Negev, Beer-Sheva, Israel) and
described in our previous article [47]. The plasmid expressing the
Renilla luciferase via the enhancerless promoter pRL-null (pRL-
renilla) was purchased from Promega Corporation (Madison WI,
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each expressing a different shRNA clone for each of the studied
target genes, were purchased from Sigma-Aldrich Corporation.
To choose the most appropriate shRNA clones for our
experiments their silencing efficiency and specificity were tested
by Western analysis of their target proteins with comparison to
several randomly selected unrelated proteins (not shown).
Plasmids were transfected at the indicated combinations by the
jetPRIM
TM kit (Polyplus transfection, www.polyplus-transfec-
tion.com) according to the manufacturer’s instructions with
adjustments to a total 5 mg DNA per transfection. The
transfection efficiency, tested with GFP-expressing plasmid,
was found by FACS analysis to range in our employed cells
between 70 to 80% (not shown). Each transfection mixture
included the pRL-renilla plasmid as an internal control for
variation in transfection efficiency. The enzymatic activities were
measured at 24 hr post-transfection and the Luc activity was
normalized to that of renilla and presented as fold of the relevant
control. The plotted results represent the average of triplicate
transfections 6 SE.
Cells and culture conditions
Most experiments of this study were carried out with Jurkat and
H9 T-cells lines (kindly provided by Prof. Irvin S.Y Chen, Center
for HIV and digestive diseases, UCLA AIDS Institute, Los
Angeles, California, USA). In addition, we generated from these
cells sub-clones stably expressing shRNAs which were designated
after their target genes as follows: Jurkat/PKCa-shRNA, Jurkat/
PKCe-shRNA, Jurkat/p53-shRNA, Jurkat/c-Jun-shRNA, H9/
PKCd-shRNA, H9/PKCg-shRNA, H9/p53-shRNA and H9/c-
Jun-shRNA, We also generated Jurkat and H9 cells stably
transfected with HTLV-1 LTR-Luc. These sub-clones were
designated as Jurkat/LTR-Luc and H9/LTR-Luc. These latter
two clones were validated by checking the activation of their Luc
expression by transient transfection with the Tax expressing
plasmid (not shown). The cells were grown in RPMI-1640
supplemented with 10% fetal calf serum and antibiotics.
For long-term maintaining of stably transfected clones, they
were grown in the presence of the selective antibiotics to avoiding
overgrowth of cells that have lost the transfected construct.
However when these cells were prepared for experiments they
were grown for 1–2 days without the antibiotics to avoid their
possible side effects.
In experiments lasting more than 48 hr, the cells were sub-
cultured every two days into fresh medium containing the same
experimental ingredients and keeping approximately the same cell
density in order to avoid lowering of the medium ingredients and
to minimize cell death due to culture aging. Cell viability was
checked by the trypan blue expulsion analysis.
Antibodies
The DO-1 mouse monoclonal antibody which recognizes both
the w.t. and mutant p53 configurations and the mouse anti actin
antibody, were purchased from Calbiochem and ICN respectively.
Mouse polyclonal antibodies against Sp1, c-Jun, CREB, ATF-1,
ATF-2 and albumin, goat antibody specifically detecting c-Jun
phosphorylated at serine residues 63 and 73, (referred to as anti
phospho-c-Jun antibody), rabbit polyclonal antibodies against p53,
mouse anti p53 monoclonal antibody pAb240 (recognizing only
mutant forms of p53) and pAb1620 (recognizing only w.t. p53),
rabbit anti mouse-IgG, mouse anti rabbit-IgG and anti goat-IgG
antibodies, were all purchased from Santa Cruz Biotechnology
Inc, Santa Cruz, CA, USA.
TPA treatment in absence and presence the PKC inhibitor
bisindolylmaleimide-I (BI)
The cells were exposed to 50 nM TPA (Sigma-Aldrich
Corporation) for the indicated times. Where specified, 2 mMo f
the PKC inhibitor BI [41,59] was added one hour before TPA to
ensure its presence within the cells before PKC activation.
Cell fractionation, co-immunoprecipitation and Western
blot analyses
Whole cell lysates and subcellular fractions were prepared by
NucBuster Kit (Calbiochem, Cat. No. 71183-3), according to the
Kit’s protocol.
For co-immunoprecipitation assays aliquots of the nuclear
extracts (200 mg protein) were immunoprecipitated with the
specified mouse antibodies (Mouse IP Ab). The precipitates were
collected with protein-A/protein-G bound Sepharose beads,
washed twice to remove non-specific proteins. Then they were
dissociated and analyzed by Western blot for the co-precipitated
proteins with the respective rabbit antibodies as previously
described [41]. The specificity of the assay was verified by
subjecting the extracts to co-immunoprecipitation with non-
specific mouse IgG, For direct Western analyses aliquots of the
tested extracts (80 mg protein) were analyzed with the respective
antibodies as described elsewhere [48]. Equal loading of samples
was assessed by stripping the blot from the first antibodies and re-
processing it with anti-actin antibody.
Electrophoretic mobility shift and supershift assay
Aliquots of 6 mg nuclear proteins of the tested cells were
examined for binding to 39-biotin-labeled double stranded
oligonucleotides carrying the sequence of the 21 bp TRE III (its
upper strand is 59-CAGGCGTTGACGACAACCCCT-39. The
bold letters represent a core octanucleotide sequence which is an
imperfect match of the cyclic AMP responsive element, CRE, that
partially overlaps the phorbol ester/AP-1 responsive element [62])
or of the Ets responsive region 1 (ERR-1) of the LTR (its upper
strand is 59-CCTCCGGGAAGCCACCAAGAACCACCCAT-
TTCCTCCCCATGTTTG-39. The bold letters represent an
Sp1 binding site) by electrophoretic mobility shift assay (EMSA)
using the LightShiftH Chemiluminescent EMSA kit (PIERCE,
Rockford, IL) as instructed by the supplier. The binding specificity
was assessed by competition with 50 fold molar excess of unlabeled
oligonucleotide of the relevant probe versus its mutated oligonu-
cleotide carrying the following nucleotide substitutions (marked by
underlined bold small letters): In TRE III: 59-CAGGCGTTGAt-
GACAACCCCT-39 and ERR-1: 59-CCTCCGGGAAGCCAC-
CAAGAACtAatCATTTCCTCCCCATGTTTG-39, The bound
proteins were identified by supershift analysis with the respective
antibodies according to the kit’s protocol. To increase the accuracy
and reliability of the supershift data we applied increasing amounts
(1, 2 and 4 mg) of each of the employed antibodies.
DNA-protein pull-down assay
Nuclear extracts (200 mg protein) of the tested H9 and Jurkat
cells were mixed with 1 mgo r6mg of the above mentioned 39-
biotin-labeled TRE III or ERR-1 oligonucleotide probes and
10 mg sheared salmon sperm DNA in pull-down buffer (10 mM
HEPES, pH 7.9, 25 mM KCl, 500 mM DTT, 2.5% glycerol and
protease inhibitor cocktail) and incubated in ice for 90 min. Then
Streptavidin-linked agarose beads (70% slurry) were added and the
mixtures were gently rotated overnight at 4uC. The beads were
then pelleted and washed with cold pulled-down buffer. The
bound proteins were released from the beads by heating at 95uC
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resis (PAGE) and identified by Western blot analysis with the
indicated antibodies.
Chromatin immunoprecipitation assay (ChIP)
HTLV-1 LTR-Luc stably-transfected Jurkat (Jurkat/LTR-Luc)
and H9 (H9/LTR-Luc) cells (2610
7) were treated with TPA for
the indicated time and their chromatin was cross-linked by adding
formaldehyde (1% final concentration) to the cultures for 10 min
at room temperature. The formaldehyde was quenched by glycine
(125 mM final concentration) with shaking for 5 min. Then the
cells were washed 3 times with ice-cold PBS and suspended in
750 ml lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl and
protease inhibitor cocktail). The lysates were sonicated (10615 sec
pulses) on ice to generate 400–600 bp fragments and centrifuged
for 30 sec at 4uC to remove cell debris. The supernatants
containing the fragmented chromatin were diluted 10 fold in
ChIP buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl,
20 mM Tris-HCl and protease inhibitor cocktail), cleared by
incubation with protein-A/protein-G bound Sepharose beads for
2h ra t4 uC and the cleared supernatant was splitted into equal
aliquots. One aliquot was saved for quantifying the input DNA,
whereas the others were immunoprecipitated by incubation with
the indicated amounts (2–8 mg) of the tested antibodies for
overnight at 4uC. The immunoprecipated chromatin fragments
were collected by incubation with the protein-A/protein-G bound
Sepharose beads for 1 hr at 4uC, washed 3 times with ChIP buffer.
The DNA-protein cross-linking of these and the input aliquots was
reversed by incubation in ChIP buffer containing proteinase K for
2h ra t6 5 uC and then for additional 10 min at 95uC. The free
DNA fragments were purified by the QIAquick PCR Purification
kit (Qiagen) and amplified by real-time PCR using primers that
flanked the segment between nucleotides 2321 and 297 in the U3
region of the integrated LTR. This segment included the three
21 bp TRE repeats and the ERR-1 region which is located
between TRE-II and TREIII (forward: 59-TTCCGAGAAACA-
GAAGTCTG; reverse: 59-GTGAGGGGTTGTCGTCA (see ref
[63,64]). The PCR DNA products were analyzed by 1.2% agarose
gel electrophoresis.
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